{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:22:44Z","timestamp":1794291764889,"version":"4.9.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In clinical trials, poly (ADP-ribose) polymerase inhibitors (PARPi) versus chemotherapy resulted in significantly improved progression-free survival, manageable adverse event profiles, and favorable patient-reported outcomes (PROs) in patients with human epidermal growth factor receptor 2\u2013negative (HER2\u2212) advanced breast cancer (ABC) and germline <jats:italic>BRCA1\/2<\/jats:italic> mutations (g<jats:italic>BRCA1\/2<\/jats:italic>mut). The objective of this study was to evaluate PROs and physician satisfaction with treatment in patients with g<jats:italic>BRCA1\/2<\/jats:italic>mut HER2\u2212 ABC receiving PARPi or physician\u2019s choice of chemotherapy in a multi-country, real-world setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective analysis used data from the Adelphi Real World ABC Disease Specific Programmes in the United States, European Union, and Israel. PROs were assessed at a single timepoint using the EuroQol 5-Dimensions 5-Level (EQ-5D-5L) scale, Cancer Therapy Satisfaction Questionnaire (CTSQ), and European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30) and the breast cancer\u2212specific module (QLQ-BR23). Baseline PROs were not assessed. Physician satisfaction with treatment scores was dichotomized to a 0\/1 variable (0\u2009=\u2009very dissatisfied\/dissatisfied\/moderately satisfied; 1\u2009=\u2009satisfied\/very satisfied). Scores were compared using inverse-probability\u2212weighted regression adjustment, controlling for multiple confounding factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study included 96 patients (PARPi, <jats:italic>n<\/jats:italic>\u2009=\u200938; platinum\/non\u2013platinum-based chemotherapy, <jats:italic>n<\/jats:italic>\u2009=\u200958). Patients receiving PARPi versus chemotherapy reported significantly better scores on the EQ-5D-5L Health Utility Index. On the EORTC QLQ-C30 functional scales, patients receiving PARPi reported significantly better scores (mean\u2009\u00b1\u2009SE) for physical functioning (80.0\u2009\u00b1\u20092.4 vs 71.9\u2009\u00b1\u20093.4; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) and social functioning (82.0\u2009\u00b1\u20096.2 vs 63.6\u2009\u00b1\u20093.7; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) and, on the symptom scales, reported significantly better scores for constipation (1.9\u2009\u00b1\u20091.8 vs 18.7\u2009\u00b1\u20093.2; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), breast symptoms (0.4\u2009\u00b1\u20093.9 vs 13.3\u2009\u00b1\u20092.6; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), arm symptoms (2.6\u2009\u00b1\u20091.3 vs 11.4\u2009\u00b1\u20092.4; <jats:italic>p<\/jats:italic>\u2009=\u20090.001), and systemic therapy side effects (13.5\u2009\u00b1\u20091.8 vs 29.4\u2009\u00b1\u20092.3; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). In contrast, patients receiving chemotherapy scored significantly better on the nausea\/vomiting scale (18.3\u2009\u00b1\u20092.8 vs 34.5\u2009\u00b1\u20095.1; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Patients receiving PARPi reported numerically better satisfaction scores on the CTSQ scales. Physicians were more likely to be satisfied\/very satisfied with PARPi versus chemotherapy (95.4%\u2009\u00b1\u20097.3% vs 40.8%\u2009\u00b1\u20096.2%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The PRO findings in this real-world population of patients with g<jats:italic>BRCA1\/<\/jats:italic>2mut HER2\u2212 ABC complement those from the pivotal clinical trials, providing further support for treatment with PARPi in these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10325-9","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T09:05:54Z","timestamp":1671699954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1\/2-mutated human epidermal growth factor receptor 2\u2013negative advanced breast cancer from the United States, Europe, and Israel"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7711-8627","authenticated-orcid":false,"given":"Reshma","family":"Mahtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Niyazov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhakti","family":"Arondekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Massey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Patrick","family":"Lux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"10325_CR1","unstructured":"US Food and Drug Administration. FDA approves olaparib for germline BRCA-mutated metastatic breast cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olaparib-germline-brca-mutated-metastatic-breast-cancer. Accessed 31 Jan 2022."},{"key":"10325_CR2","unstructured":"US Food and Drug Administration. FDA approves talazoparib for gBRCAm HER2-negative locally advanced or metastatic breast cancer. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-talazoparib-gbrcam-her2-negative-locally-advanced-or-metastatic-breast-cancer. Accessed 31 Jan 2022."},{"issue":"6","key":"10325_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523\u201333.","journal-title":"N Engl J Med"},{"issue":"8","key":"10325_CR4","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee K-H, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753\u201363.","journal-title":"N Engl J Med"},{"issue":"4","key":"10325_CR5","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","volume":"30","author":"ME Robson","year":"2019","unstructured":"Robson ME, Tung N, Conte P, Im S-A, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558\u201366.","journal-title":"Ann Oncol"},{"issue":"11","key":"10325_CR6","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","volume":"31","author":"JK Litton","year":"2020","unstructured":"Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Goncalves A, et al. Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31(11):1526\u201335.","journal-title":"Ann Oncol"},{"issue":"12","key":"10325_CR7","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andre F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623\u201349.","journal-title":"Ann Oncol"},{"issue":"7\u20138","key":"10325_CR8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1159\/000521826","volume":"45","author":"LE Hillebrand","year":"2022","unstructured":"Hillebrand LE, Soling U, Marschner N. The significance of patient-reported outcomes for metastatic breast cancer patients. Oncol Res Treat. 2022;45(7\u20138):423\u20139.","journal-title":"Oncol Res Treat"},{"issue":"23","key":"10325_CR9","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence - what is it and what can it tell us? N Engl J Med. 2016;375(23):2293\u20137.","journal-title":"N Engl J Med"},{"issue":"11","key":"10325_CR10","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"key":"10325_CR11","volume-title":"EphMRA Code of Conduct","author":"European Pharmaceutical Market Research Association","year":"2020","unstructured":"European Pharmaceutical Market Research Association. EphMRA Code of Conduct. 2020. https:\/\/www.ephmra.org\/code-conduct-aer. Accessed 1 Sept 2021."},{"key":"10325_CR12","unstructured":"US Department of Health & Human Services. Summary of the HIPAA Privacy Rule. https:\/\/www.hhs.gov\/hipaa\/for-professionals\/privacy\/laws-regulations\/index.html. Accessed 10 Aug 2022."},{"issue":"10","key":"10325_CR13","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"issue":"5","key":"10325_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"10325_CR15","volume-title":"EORTC QLQ-C30 scoring manual: European organisation for research and treatment of Cancer","author":"PM Fayers","year":"2001","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. EORTC QLQ-C30 scoring manual: European Organisation for Research and Treatment of Cancer; 2001."},{"issue":"10","key":"10325_CR16","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1200\/JCO.1996.14.10.2756","volume":"14","author":"MA Sprangers","year":"1996","unstructured":"Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14(10):2756\u201368.","journal-title":"J Clin Oncol"},{"issue":"4","key":"10325_CR17","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1524-4733.2007.00310.x","volume":"11","author":"PC Trask","year":"2008","unstructured":"Trask PC, Tellefsen C, Espindle D, Getter C, Hsu MA. Psychometric validation of the cancer therapy satisfaction questionnaire. Value Health. 2008;11(4):669\u201379.","journal-title":"Value Health"},{"issue":"5","key":"10325_CR18","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708\u201315.","journal-title":"Value Health"},{"issue":"9","key":"10325_CR19","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1093\/annonc\/mdy257","volume":"29","author":"J Ettl","year":"2018","unstructured":"Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Goncalves A, et al. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1\/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018;29(9):1939\u201347.","journal-title":"Ann Oncol"},{"key":"10325_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejca.2019.06.023","volume":"120","author":"M Robson","year":"2019","unstructured":"Robson M, Ruddy KJ, Im SA, Senkus E, Xu B, Domchek SM, et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. Eur J Cancer. 2019;120:20\u201330.","journal-title":"Eur J Cancer"},{"key":"10325_CR21","unstructured":"German Guideline Program in Oncology (GGPO). Evidence-based guideline for the early detection, diagnosis, treatment and follow-up of breast cancer; version 4.4. AWMF. https:\/\/register.awmf.org\/assets\/guidelines\/032_D_Krebsgesellschaft\/032-045OLeng_S3_Guideline_Breast_Cancer_2021-11.pdf. Accessed 16 Dec 2022."},{"key":"10325_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-5-70","volume":"5","author":"AS Pickard","year":"2007","unstructured":"Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.","journal-title":"Health Qual Life Outcomes"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10325-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10325-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10325-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T09:06:20Z","timestamp":1671699980000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10325-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10325"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10325-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"assertion":[{"value":"9 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients provided informed consent for use of their anonymized and aggregated data for research and in scientific publications. Data were aggregated and de-identified before receipt by Adelphi Real World. This research was approved by the Western Institutional Review Board (study protocol AG8643). Data collection was undertaken in line with European Pharmaceutical Marketing Research Association guidelines and, as such, did not require ethics committee approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RM has acted as consultant for Agendia, Amgen, AstraZeneca, Daiichi-Sankyo, Eisai, Genentech, Gilead, Hologic, Eli Lilly, Merck, Novartis, Pfizer, Puma, Sanofi, and SeaGen; and has contracted research for AstraZeneca, Genentech, and Veru.AN, BA are employees of and own stock in Pfizer Inc.KL, AR, and LM are employees of Adelphi Real World.MPL has received honoraria for lectures, consulting, and\/or working in an advisory role for Eli Lilly, AstraZeneca, MSD, Novartis, Pfizer, Eisai, Exact Sciences, Daiichi-Sankyo, Gr\u00fcnenthal, Gilead, Pierre Fabre, PharmaMar, Onkowissen, and Roche; received fees for travel, accommodations, and\/or expenses from Roche and Pfizer; acted as editorial board member of Medac; and received fees for non-CME services from Eli Lilly, Roche, MSD, Novartis, Pfizer, Exact Sciences, Daiichi-Sankyo, Gilead, Gr\u00fcnenthal, AstraZeneca, and Eisai.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1343"}}